How to Choose Between Wegovy and Mounjaro Online
Online Prescription Process for Wegovy or Mounjaro Weight Loss Treatment
Getting prescribed Wegovy or Mounjaro for weight loss online eliminates the traditional barriers of lengthy GP waiting lists and referral processes. EverydayMeds has developed a comprehensive 3-minute clinical assessment that captures all the medical information a prescriber needs to make an informed decision about your suitability for either treatment. The assessment covers your medical history, current medications, BMI calculation, and specific contraindications for both semaglutide and tirzepatide therapies.
Once submitted, your assessment is reviewed by a licensed UK prescriber within our standard 3 working day timeframe, though express 24-hour review is available for those who need faster access to treatment. This online approach means you can access Wegovy or Mounjaro for weight loss from anywhere in the UK, without geographical limitations or the need to take time off work for appointments. Our GPhC-registered pharmacy (#9012878) ensures every prescription meets the highest clinical and legal standards.
Wegovy vs Mounjaro Pricing and Value for Online Weight Loss Treatment
Understanding the cost structure for Wegovy or Mounjaro weight loss treatment helps you plan your investment in long-term weight management. Wegovy follows a mandatory dose escalation schedule starting at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing through £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), £139.99 for 1.7mg (weeks 13-16), and reaching the maintenance dose of 2.4mg at £209.99 from week 17 onwards. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Our bundle options provide convenience for those committed to their Wegovy or Mounjaro weight loss journey, such as the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99, covering your first 12 weeks of treatment in a single order. The Ultimate Stability Trio offers three maintenance 2.4mg pens for £649.99, ensuring consistent supply without the need for monthly reordering. These bundles eliminate the anxiety of potential supply interruptions whilst providing streamlined delivery scheduling.
Clinical Evidence Supporting Wegovy or Mounjaro for Weight Loss
The clinical foundation for choosing Wegovy or Mounjaro for weight loss rests on extensive trial data from different study populations and methodologies. In the STEP trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% at 2 years, indicating long-term efficacy when treatment continues.
Mounjaro's SURMOUNT trials showed different results due to its dual GIP and GLP-1 receptor mechanism, though direct comparison between trials isn't clinically appropriate due to varying study designs and patient populations. Both treatments require ongoing commitment, as the STEP 1 extension study showed patients regained approximately two-thirds of weight lost within one year of stopping treatment, emphasising that weight management is a long-term commitment.
How Wegovy Works for Weight Loss Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of a natural hormone called glucagon-like peptide-1, which your body normally produces in response to food intake. This mechanism works primarily on the brain's appetite centres, reducing feelings of hunger and promoting earlier satiety after smaller meals. The medication may also slow gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Clinical studies suggest that Wegovy can reduce food cravings and the psychological drive to eat, though individual responses vary considerably. Unlike stimulant-based appetite suppressants, Wegovy works through natural hormonal pathways, which explains why it must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Streamlined Ordering Process for Wegovy or Mounjaro Weight Loss Treatment
The EverydayMeds ordering process for Wegovy or Mounjaro weight loss treatment begins with our comprehensive 3-minute clinical assessment, designed to capture all relevant medical information without unnecessary complexity. After submission, your application enters our clinical review system where licensed UK prescribers evaluate your suitability for either semaglutide or tirzepatide based on current MHRA guidelines and NICE recommendations. Once approved, your prescription-only medicine is prepared by our GPhC-registered pharmacy (#9012878) and dispatched via our temperature-controlled cold-chain delivery system. Standard next-day delivery ensures your medication maintains its efficacy from our pharmacy to your door, with tracking provided at every stage. This entire process, from assessment to delivery, typically completes within 4-5 days, significantly faster than traditional healthcare pathways.
Storage and Practical Considerations for Wegovy or Mounjaro Weight Loss Treatment
Proper storage significantly impacts the effectiveness of your Wegovy or Mounjaro weight loss treatment, with both requiring refrigeration at 2-8°C before first use. Wegovy offers a practical advantage for travel and lifestyle flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. Both medications use pre-filled FlexTouch pens that deliver precise weekly doses subcutaneously, typically into the abdomen, thigh, or upper arm. The mandatory dose escalation schedule for Wegovy cannot be skipped or accelerated, as this increases the risk of gastrointestinal side effects. Understanding these practical elements ensures you can integrate your chosen weight loss treatment seamlessly into your daily routine whilst maintaining medication efficacy.
Personalised Treatment Selection for Wegovy or Mounjaro Weight Loss Success
The decision between Wegovy or Mounjaro for weight loss often depends on individual medical factors that our online assessment process carefully evaluates. Wegovy's single GLP-1 receptor mechanism may suit patients who respond well to appetite suppression, whilst Mounjaro's dual GIP and GLP-1 approach offers a different therapeutic profile for those who haven't achieved desired results with GLP-1 monotherapy. Our prescribers consider your previous weight loss attempts, concurrent medications, and specific health conditions to recommend the most appropriate option.
This personalised approach extends beyond initial prescription to ongoing support throughout your weight management journey. Both Wegovy and Mounjaro are available from EverydayMeds, allowing our prescribers to switch treatments if clinical circumstances change or if one medication proves more effective than the other. Our online platform maintains detailed treatment records, enabling continuity of care and informed decision-making about dose adjustments or treatment modifications.
Start Your Wegovy or Mounjaro Weight Loss Journey Today
Beginning your Wegovy or Mounjaro weight loss treatment through EverydayMeds combines clinical expertise with practical convenience, removing traditional barriers to accessing prescription weight management medication. New customers can apply discount code FIRST40 at checkout, whilst existing patients use DOSE25 to access our competitive pricing structure. Our licensed prescribers are available to answer questions about treatment selection, and our pharmacy team ensures seamless delivery coordination for ongoing treatment. Visit https://everydaymeds.co.uk/collections/wegovy to complete your 3-minute assessment and take the first step towards medically-supervised weight management. Remember that both treatments work best alongside lifestyle modifications, and our clinical team remains available to support your journey towards sustainable weight loss goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
